Your browser doesn't support javascript.
loading
Cardiovascular screening outcomes in the Dutch survivorship care program for Hodgkin lymphoma survivors.
Lammers, Eline M J; Nijdam, Annelies; Zijlstra, Josée M; Janus, Cécile P M; de Weijer, Roel J; Appelman, Yolande; Manintveld, Olivier C; Teske, Arco J; van Leeuwen, Flora E; Aleman, Berthe M P.
Afiliação
  • Lammers EMJ; Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Nijdam A; Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Zijlstra JM; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Cancer Centre Amsterdam, Amsterdam, The Netherlands.
  • Janus CPM; Department of Radiation Oncology, Erasmus Medical Centre, Rotterdam, The Netherlands.
  • de Weijer RJ; Department of Hematology, University Medical Centre Utrecht, Utrecht, The Netherlands.
  • Appelman Y; Department of Cardiology, Amsterdam UMC, Location Vrije Universiteit, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.
  • Manintveld OC; Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands.
  • Teske AJ; Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands.
  • van Leeuwen FE; Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Aleman BMP; Department of Radiation Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. b.aleman@nki.nl.
J Cancer Surviv ; 2024 Apr 23.
Article em En | MEDLINE | ID: mdl-38649650
ABSTRACT

PURPOSE:

Hodgkin lymphoma (HL) survivors are at increased risk of cardiovascular disease (CVD) due to former lymphoma treatment. In 2013, cardiovascular screening for 5-year HL survivors according to national guidelines was implemented in Dutch survivorship clinics. We aim to assess the following (1) adherence to screening guidelines and (2) the yield of (risk factors for) CVD in the screening program.

METHODS:

The study population consisted of 5-year HL survivors who received survivorship care at three University Medical Centers from 2013 to 2016 through 2021. Patient characteristics, cardiovascular screening procedures, and outcomes were collected from the medical records.

RESULTS:

In 186 survivors eligible for cardiovascular screening (mean age 47.8 years, 60.8% female), the following diagnostics were performed complete blood tests (81.0%, median frequency yearly instead of advised 5-yearly evaluation), electrocardiogram (93.0%), echocardiography (94.6%). Fifty-five percent of survivors had at least one modifiable cardiovascular risk factor (i.e., current smoking, overweight, new/insufficiently controlled hypertension, dyslipidemia, or diabetes). Screening detected ≥ 1 CVD in 31.1% of survivors. Among survivors with available echocardiography report (n = 106), screening detected new aortic and/or mitral valve dysfunction(s) in 51.0% (with grades 3-4 in 4.9%) and impaired left ventricular ejection fraction in 10.3%.

CONCLUSIONS:

Adherence to the screening guidelines in the Dutch HL survivorship care program was reasonable to good and a substantial number of actionable (risk factors for) CVD were diagnosed. IMPLICATIONS FOR CANCER SURVIVORS Our findings inform HL survivors at high risk of late cardiotoxicity about cardiovascular screening findings and demonstrate appropriate therapeutic actions after diagnosis of (risk factors for) CVD.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article